Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives
Diatech Pharmacogenetics (“Diatech” or “the Company”), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (“TA”), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in the Company. As part of the transaction, minority investor Alto Partners will fully exit its stake in the business. Diatech’s founder and management team will retain majority ownership of the Company, partnering closely with TA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005178/en/
Diatech produces and distributes genomics testing solutions to identify gene mutations and genetic differences that are targets of personalized cancers therapies and that influence patient responses to specific treatments. With these tests, Diatech aims to increase the effectiveness of cancer medicine through personalized diagnosis and treatments.
“We are excited to welcome TA on this journey with us amid a period of great advancement in precision medicine,” said Fabio Biondi, Founder and President of Diatech. “TA offers extensive operational experience and a wide global network that will be critical as we strive to accelerate our international growth and product innovation. We also thank Alto Partners for helping us reach this milestone in our growth journey.”
Founded in 1996, Diatech has demonstrated strong growth in recent years and today is among the first players into the EU market for oncology diagnostics. TA’s investment will support Diatech’s continued development of market-leading diagnostic solutions and reagents in the pharmacogenetics sectors, as well as its global growth initiatives, furthering the Company’s position as a leader in the rapidly expanding molecular diagnostics market.
“As technology improves and there is a greater shift toward precision medicine, continued advancements in the genomic testing landscape are essential,” said Oliva Alberti, CEO of Diatech. “This strategic partnership with TA will allow us to widen the reach of our existing products and services, while also making a meaningful expansion into international markets.”
“Diatech’s comprehensive, market-leading product portfolio highlights the Company’s commitment to a rigorous and differentiated R&D process that consistently drives value creation,” said Lovisa Lander, Director at TA. “We look forward to partnering with Fabio, Oliva, and the entire management team to support Diatech’s international and domestic growth journey.”
“The Company’s proven track record and leading position in its market mean it is well positioned to capitalize on organic and inorganic growth opportunities, expanding its addressable market and extensive product portfolio,” said Birker Bahnsen, Managing Director at TA and head of the firm’s Europe Healthcare Group. “We are thrilled to support Diatech on its next phase of growth.”
“Since our investment in 2021, Diatech has achieved strong organic growth, expanded into new global markets and broadened its product portfolio,” said Enrico Ricotta, Senior Partner at Alto Partners. “It has been a privilege to work with the entire Diatech team and we wish them the best as they build on their continued success in partnership with TA.”
The transaction is expected to close in the second quarter of 2023 pending customary regulatory approval.
Financial terms of the transaction were not disclosed.
About Diatech Pharmacogenetics
Diatech Pharmacogenetics is a leading Italian company in the development, production and commercialization of molecular diagnostic tools for precision oncology medicine. Founded in 1996, the company aims to simplify complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acid extraction and molecular analysis to final reporting. Diatech has shown strong growth in recent years and today is among the first players in the EU market for the oncology diagnostics market. To learn more, visit www.diatechpharmacogenetics.com
About TA
TA Associates (“TA”) is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $48.6 billion in capital to date and has more than 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit www.ta.com.
About Alto Partners
Alto Partners SGR, an independent company, is controlled by its expert multidisciplinary team to promote and manage private equity funds investing in small-to-medium-sized Italian companies. Alto Partners is a proven experienced, professional and reliable partner in supporting the medium-to-long-term development of our portfolio companies. Together, Alto Partners SGR works alongside industrial families and managers to oversee generational transitions and growth programs. To learn more, visit www.altopartners.it.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005178/en/
Contact information
Maggie Benoit
Communications Manager, TA
mbenoit@ta.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 11:53:00 EET | Press release
Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where high-quality assets can be tightly held. The Fund holds positions in the 2nd and 3rd largest commercial timberlands estates in New Zealand, one of Australia’s largest softwood forest
Smartstream Introduces Agentic AI ‘Smart Agents’ for Investigations and Exceptions Handling4.12.2025 10:55:00 EET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the preview of Smart Agents for Investigations, a breakthrough in financial operations that brings augmented and autonomous exception handling to reconciliations and back-office processes. The new investigation agent combines domain-trained AI agents, workflow adoption, and embedded controls to triage, investigate, resolve, and learn from exceptions - reducing manual effort, accelerating time to resolution, and strengthening auditability. It will add a layer of intelligence on top of Smartstream’s current reconciliations and exceptions solutions. It understands the breaks context, adheres to customer playbooks and reaches out for missing information. It documents every step for audit and compliance, allowing analysts to focus on risk. Finally, it augments the analyst’s investigation with contextual information radically changing the user experience to review and a
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes4.12.2025 10:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA™ platform to optimise NANOBODY® molecules for multiple new targets in the area of inflammation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204759388/en/ “We are truly excited about this new collaboration with Sanofi,”said LabGenius’ CSO, Dr. Angus Sinclair. “This partnership serves as strong validation of our platform’s unique ability to tackle complex antibody co-optimisation challenges across
GoWit One: The Unified AI Operating System Set to Revolutionize Commerce & Retail Media4.12.2025 08:09:00 EET | Press release
GoWit, a global AdTech leader in omnichannel Commerce and Retail Media, announced the launch of GoWit One, the unified AI operating system that brings automation, unification, and real-time intelligence into a single ad platform for agencies operating across multiple retailers, channels, and markets. By bringing these three elements into one dashboard, GoWit One addresses the industry's most critical bottleneck: operational inefficiency. The platform enables agencies to manage campaigns across multiple retailers, channels, and markets, reducing manual AdOps workflows by 98%, turning a process that used to take hours into as little as 10 minutes. Solving the “Fragmentation Crisis” Despite the explosive growth of Retail Media, the industry faces a significant hurdle. According to the IAB, 70% of the market still lacks end-to-end AI adoption. Media buyers are currently forced to juggle disconnected networks, compliance rules, and dashboards, leading to manual errors and an inability to sc
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings4.12.2025 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation. S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow. The agency also notes Galderma’s disciplined financial policy, supporting expectations of continued deleveraging over the coming years. The positive outlook indicates that an upgrade could be considered over the next 12–24 months subject to Galderma continuing to deliver profitable g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom